Exponential Volume in Keryx (KERX, AEZS)

Posted in General 
August 3rd, 2009

Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is up huge after the company announced an agreement with the FDA on a Special Protocol Assessment for its Phase 3 Trial of KRX-0401 in the treatment of multiple myeloma.  KERX is up almost 50% from this morning’s news and we have seen almost 9.9 million shares trade hands as of 10:38 AM ESt.  This trades an average of about 2.2 million shares and its 52-week range is $0.09 to $1.88.

This news also has partner Aeterna Zentaris Inc. (NASDAQ: AEZS) trading up nearly 7% at $2.80 on 490,000 shares.  Its 52-week range is $0.26 to $3.25 and average volume is 235,000 shares.

Jon C. Ogg
August 3, 2009 (10:38 AM EST)

Comments are closed